Edition:
United Kingdom

NantKwest Inc (NK.OQ)

NK.OQ on NASDAQ Stock Exchange Global Select Market

4.74USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,941
52-wk High
$8.43
52-wk Low
$2.71

Latest Key Developments (Source: Significant Developments)

Altor Bioscience and NantKwest announces co-development agreement
Tuesday, 4 Oct 2016 

NantKwest Inc: Financial terms of this co-development are not disclosed . Development agreement to advance innovative natural killer cell combination immunotherapies for the treatment of cancer . Altor and Co will exclusively collaborate on development of therapeutic applications combining altor's proprietary IL-15 superagonist .Altor, Co to also exclusively collaborate single-chain t cell receptor/IL-2 fusion protein products with Co's proprietary NK cell therapy platforms.  Full Article

BRIEF-Nantkwest announces publication of preclinical data of hank cell therapy

* Nantkwest announces publication of preclinical data of hank cell therapy in combination with checkpoint inhibitor avelumab providing strong rationale for advancement to human clinical trials Source text for Eikon: Further company coverage: